CLOV is trading above its 50‑day SMA within an ascending channel, and Q2 earnings posted 22% YoY revenue growth with a narrowed loss per share. The Star Plan “A” rating upgrade and UnitedHealth’s Medicaid margin outlook reinforce the bullish fundamentals.

Investor sentiment has surged after UnitedHealth’s optimistic Medicaid outlook and the Star Plan rating, driving a 12% price rally this week. Elevated short‑interest coverage and social‑media buzz confirm bullish market momentum.

Long‑term, Clover gains from expanding Medicare Advantage enrollment and a favorable Medicaid margin floor, though regulatory and provider‑contract concentration risks remain. Improved loss profile and a growing partnership pipeline keep the risk‑adjusted outlook bullish.

Technicals show RSI at 62, MACD line crossing above the signal line, and volume up 35% on a breakout above the $8 resistance level. The price is now above the 200‑day EMA and stochastic divergence points to further upside.